Across TCGA pan-cancer cohorts, RRP8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RRP8 data layer compared with 17 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher RRP8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RRP8 expression acts as an unfavorable survival marker.
COAD, STAD, and UCEC are the cancer types where RRP8 Mutation most reproducibly stratifies survival.